Lung cancer mortality has decreased over the past decade and can be partly attributed to
advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have …

Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves
surgery in combination with postoperative (adjuvant) platinum-based chemotherapy where …

Lung squamous cell carcinoma (LSCC) is the most common subtype of non-small cell lung
cancer. Immunotherapy has become an effective treatment in recent years, while patients …

Colorectal cancer (CRC) liver metastasis accounts for the majority of fatalities associated
with CRC. Early detection of metastasis is crucial for improving patient outcomes but can be …

Background Synergistic anti-tumor effects were observed in vivo and in vitro when immune
checkpoint inhibitors (ICIs) were combined with denosumab. However, the clinical benefit …

Introduction Lung squamous cell carcinoma (LUSC) is a unique subform of nonsmall cell
lung cancer (NSCLC). The lack of specific driver genes as therapeutic targets leads to worse …

Cancer remains a significant global health challenge with limited treatment options beyond
systemic therapies, such as chemotherapy, radiotherapy, and molecular targeted therapy …

The present hypothesis was to identify the potential of sorafenib tosylate (ST) loaded
liposomal dry powder inhaler (ST-LDPI) for targeting non-small cell lung cancer (NSCLC) …

Context• A wide variety of malignancies common to humans display abnormal constitutive
expression of nuclear factor kappa beta (NF-κβ). The study of NF-κβ can increase …

Giant cell tumor of bone (GCTB) is an intermediate malignant bone tumor that is locally
aggressive and rarely metastasizes. Denosumab, which is a receptor activator of nuclear …